Department of Oncology, University of Oxford, Oxford, UK.
Radiation Oncology Unit, Pisa University Hospital.
Curr Opin Oncol. 2022 Nov 1;34(6):705-712. doi: 10.1097/CCO.0000000000000902. Epub 2022 Sep 12.
Gliomas are the most common primary tumors of the central nervous system. They are characterized by a disappointing prognosis and ineffective therapy that has shown no substantial improvements in the past 20 years. The lack of progress in treating gliomas is linked with the inadequacy of suitable tumor samples to plan translational studies and support laboratory developments. To overcome the use of tumor tissue, this commentary review aims to highlight the potential for the clinical application of liquid biopsy (intended as the study of circulating biomarkers in the blood), focusing on circulating tumor cells, circulating DNA and circulating noncoding RNA.
Thanks to the increasing sensitivity of sequencing techniques, it is now possible to analyze circulating nucleic acids and tumor cells (liquid biopsy).
Although studies on the use of liquid biopsy are still at an early stage, the potential clinical applications of liquid biopsy in the study of primary brain cancer are many and have the potential to revolutionize the approach to neuro-oncology, and importantly, they offer the possibility of gathering information on the disease at any time during its history.
神经胶质瘤是中枢神经系统最常见的原发性肿瘤。其预后较差，治疗效果不佳，在过去 20 年中没有实质性的改善。神经胶质瘤治疗进展缓慢，与缺乏合适的肿瘤样本以规划转化研究和支持实验室发展有关。为了克服对肿瘤组织的依赖，本评论性综述旨在强调液体活检（旨在研究血液中循环生物标志物）的临床应用潜力，重点关注循环肿瘤细胞、循环 DNA 和循环非编码 RNA。
由于测序技术的灵敏度不断提高，现在可以分析循环核酸和肿瘤细胞（液体活检）。
尽管液体活检的研究仍处于早期阶段，但液体活检在原发性脑癌研究中的潜在临床应用很多，有可能彻底改变神经肿瘤学的治疗方法，重要的是，它提供了在疾病史的任何时间收集疾病信息的可能性。
